# PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

> **NCT00682565** · PHASE2 · COMPLETED · sponsor: **Cytokinetics** · enrollment: 94 (actual)

## Conditions studied

- Heart Failure
- Myocardial Ischemia
- Angina Pectoris

## Interventions

- **DRUG:** CK-1827452 24mg and 6 mg iv infusion
- **DRUG:** CK-1827452 12.5mg capsule
- **DRUG:** CK-1827452 48 mg and 11 mg iv infusion
- **DRUG:** CK-1827452 25mg capsule
- **DRUG:** Placebo iv infusion
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT00682565
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-11
- **Final completion:** 2009-03
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00682565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00682565, "PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00682565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*